Stay updated on VIS649 Safety and Efficacy in IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the VIS649 Safety and Efficacy in IgA Nephropathy Clinical Trial page.

Latest updates to the VIS649 Safety and Efficacy in IgA Nephropathy Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe revision label on the page has been updated from v3.6.5 to v3.6.6, signaling a small update to the document/version of the page.SummaryDifference0.0%

- Check17 days agoChange DetectedAn NIH grant/contract entry was added to the study identifiers, indicating NIH funding associated with the trial.SummaryDifference0.0%

- Check31 days agoChange DetectedRevision updated from v3.6.4 to v3.6.5 in the study documentation. This indicates a minor, internal update to the study materials.SummaryDifference0.0%

- Check53 days agoChange DetectedPage revision updated from v3.6.3 to v3.6.4. This reflects a minor metadata update to the document without changes to visible content.SummaryDifference0.0%

- Check60 days agoChange DetectedA new publication citation has been added under Publications describing a study on ENVISION trial data related to the investigational agent and IgA nephropathy; it indicates ongoing dissemination of related research.SummaryDifference0.0%

- Check75 days agoChange DetectedRevision label updated from v3.6.0 to v3.6.3. This indicates a newer version of the study documentation associated with the page.SummaryDifference0.0%

Stay in the know with updates to VIS649 Safety and Efficacy in IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the VIS649 Safety and Efficacy in IgA Nephropathy Clinical Trial page.